Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma. Academic Article uri icon

Overview

abstract

  • Thirty-five patients with advanced malignant melanoma were treated with 4'-epi-doxorubicin iv once every 3 weeks. Most patients had not received prior chemotherapy and had good performance status. Three partial remissions and three minor regressions were observed. All patients experienced myelosuppression, but other toxic effects were minimal. 4'-Epi-doxorubicin has limited therapeutic activity in this disease.

publication date

  • April 1, 1984

Research

keywords

  • Antineoplastic Agents
  • Doxorubicin
  • Melanoma
  • Skin Neoplasms

Identity

Scopus Document Identifier

  • 0021327798

PubMed ID

  • 6585272

Additional Document Info

volume

  • 68

issue

  • 4